Determination of Acid α-Glucosidase Activity in Blood Spots as a Diagnostic Test for Pompe Disease
- 1 August 2001
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 47 (8) , 1378-1383
- https://doi.org/10.1093/clinchem/47.8.1378
Abstract
Background: Pompe disease is an autosomal recessive disorder of glycogen metabolism that is characterized by a deficiency of the lysosomal acid α-glucosidase. Enzyme replacement therapy for the infantile and juvenile forms of Pompe disease currently is undergoing clinical trials. Early diagnosis before the onset of irreversible pathology is thought to be critical for maximum efficacy of current and proposed therapies. In the absence of a family history, the presymptomatic detection of these disorders ideally can be achieved through a newborn-screening program. Currently, the clinical diagnosis of Pompe disease is confirmed by the virtual absence, in infantile onset, or a marked reduction, in juvenile and adult onset, of acid α-glucosidase activity in muscle biopsies and cultured fibroblasts. These assays are invasive and not suited to large-scale screening. Methods: A sensitive immune-capture enzyme activity assay for the measurement of acid α-glucosidase protein was developed and used to determine the activity of this enzyme in dried-blood spots from newborn and adult controls, Pompe-affected individuals, and obligate heterozygotes. Results: Pompe-affected individuals showed an almost total absence of acid α-glucosidase activity in blood spots. The assay showed a sensitivity and specificity of 100% for the identification of Pompe-affected individuals. Conclusions: The determination of acid α-glucosidase activity in dried-blood spots is a useful, noninvasive diagnostic assay for the identification of Pompe disease. With further validation, this procedure could be adapted for use with blood spots collected in newborn-screening programs.Keywords
This publication has 22 references indexed in Scilit:
- Approach to Gene Therapy of Glycogenosis Type II (Pompe Disease)Molecular Genetics and Metabolism, 2000
- Modulation of disease severity in mice with targeted disruption of the acid α-glucosidase geneNeuromuscular Disorders, 2000
- Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counsellingEuropean Journal of Human Genetics, 1999
- Complete correction of acid α-glucosidase deficiency in Pompe disease fibroblasts in vitro, and lysosomally targeted expression in neonatal rat cardiac and skeletal muscleGene Therapy, 1998
- Clinical and metabolic correction of pompe disease by enzyme therapy in acid maltase-deficient quail.Journal of Clinical Investigation, 1998
- Retroviral Transfer of Acidα-Glucosidase cDNA to Enzyme-Deficient Myoblasts Results in Phenotypic Spread of the Genotypic Correction by Both Secretion and FusionHuman Gene Therapy, 1997
- Prenatal diagnosis of Pompe's disease (type ii glycogenosis) in chorionic villus biopsy using maltose as a substratePrenatal Diagnosis, 1992
- Diagnosis of Pompe's disease using leukocyte preparations. Kinetic and immunological studies of 1,4-α-glucosidase in human fetal and adult tissues and cultured cellsClinica Chimica Acta; International Journal of Clinical Chemistry, 1985
- Demonstration of acid α-glucosidase in different types of Pompe disease by use of an immunochemical methodJournal of the Neurological Sciences, 1984
- Alpha-glucosidase activity in human leucocytes: Choice of lymphocytes for the diagnosis of Pompe's disease and the carrier stateClinica Chimica Acta; International Journal of Clinical Chemistry, 1978